Form 4: Astria Therapeutics Director Jonathan Violin Reports Stock Option Grant

Director Jonathan Violin reports the grant of stock options in Astria Therapeutics, Inc.

Summary

• Jonathan Violin, a director of Astria Therapeutics, Inc. [ATXS], filed a Form 4 on June 6, 2024.
• The filing reports a transaction that occurred on June 5, 2024.
• Violin was granted stock options to purchase 14,100 shares of Astria Therapeutics common stock at an exercise price of $9.18 per share.
• The options vest in full on June 5, 2025, contingent upon continued service as a director, and expire on June 4, 2034.
• Following the reported transaction, Violin directly owns 14,100 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates